![\"\"](\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/10\/4000-orion-rgb.jpg\")
<\/p>\n<\/p>\n
Orion publishes Interim Report for January-September 2020 on Wednesday 21 October 2020<\/p>\n
Orion will publish Interim Report for January-September 2020 on Wednesday, 21 October 2020 approximately at 12.00 noon EEST. The report and related presentation material will be available on the company’s website at www.orion.fi\/en\/investors after publishing.<\/p>\n
Webcast and conference call<\/strong><\/p>\n A webcast and a conference call for analysts, investors and media will be held on Wednesday, 21 October 2020 at 13.30 EEST. The event will be held only online and by conference call.<\/p>\n A link to the live webcast will be available on Orion’s website at www.orion.fi\/en\/investors. A recording of the event will be available on the website later the same day.<\/p>\n To participate the conference call, please dial:<\/p>\n Finland: +358 9 817 103 10 PIN: 15529281#<\/p>\n Silent period<\/strong><\/p>\n The silent period preceding the publication is ongoing and continues until the disclosure.<\/p>\n Publisher:<\/strong> Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are central nervous system (CNS) disorders, oncology, Finnish heritage rare diseases and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion’s net sales in 2019 amounted to EUR 1,051 million and the company had about 3,300 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.<\/p>\n Tags:<\/b> Finland: +358 9\u00a0817\u00a0103 10
Sweden: +46 8 566 426 51
UK: +44 333 300 0804
USA: +1 631 913 1422<\/p>\n
Contact person<\/strong>:
Tuukka Hirvonen, Investor Relations, Orion Corporation
tel. +358 10 426 2721<\/p>\n
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi<\/p>\nSee Campaign: <\/strong>http:\/\/www.orion.fi\/en\/investors<\/a>
Contact Information:<\/b>
Finland: +358 9817103 10
\nSweden: +46 8566426 51
\nUK: +44333 300 0804
\nUSA: +1631913 1422<\/p>\n
<\/a>, Wire<\/a>, Disclosure Newswire<\/a>, United States<\/a>, English<\/a><\/p>\n<\/div>\n
\nContact Information:<\/h3>\n
\nSweden: +46 8\u00a0566\u00a0426 51
\nUK: +44\u00a0333 300 0804
\nUSA:\u00a0 +1\u00a0631\u00a0913 1422<\/p>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"Orion publishes Interim Report for January-September 2020 on Wednesday 21 October 2020 Orion will publish Interim Report for January-September 2020 on Wednesday, 21 October 2020 approximately at 12.00 noon EEST. The report and related presentation material will be available on the company’s website at www.orion.fi\/en\/investors after publishing. Webcast and conference call A webcast and a conference call … Continue reading Orion publishes Interim Report for January-September 2020 on Wednesday 21 October 2020<\/span><\/a> Continue Reading